BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24633317)

  • 1. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.
    Weidle UH; Tiefenthaler G; Schiller C; Weiss EH; Georges G; Brinkmann U
    Cancer Genomics Proteomics; 2014; 11(1):25-38. PubMed ID: 24633317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotoxins in cancer therapy: Review and update.
    Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
    Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric fusion proteins--Pseudomonas exotoxin-based.
    Kreitman RJ
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
    Tazzari PL; de Totero D; Bolognesi A; Testoni N; Pileri S; Roncella S; Reato G; Stein H; Gobbi M; Stirpe F
    Haematologica; 1999 Nov; 84(11):988-95. PubMed ID: 10553158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy.
    Mathew M; Verma RS
    Cancer Sci; 2009 Aug; 100(8):1359-65. PubMed ID: 19459847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of anticancer immunotoxins.
    Choudhary S; Mathew M; Verma RS
    Drug Discov Today; 2011 Jun; 16(11-12):495-503. PubMed ID: 21511052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.
    Giansanti F; Flavell DJ; Angelucci F; Fabbrini MS; Ippoliti R
    Toxins (Basel); 2018 Feb; 10(2):. PubMed ID: 29438358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotoxins: is there a clinical value?
    Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A
    Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties.
    Kawakami K; Nakajima O; Morishita R; Nagai R
    ScientificWorldJournal; 2006 Jul; 6():781-90. PubMed ID: 16830050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotoxins in cancer therapy.
    Kreitman RJ
    Curr Opin Immunol; 1999 Oct; 11(5):570-8. PubMed ID: 10508704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribosome-inactivating proteins: from plant defense to tumor attack.
    de Virgilio M; Lombardi A; Caliandro R; Fabbrini MS
    Toxins (Basel); 2010 Nov; 2(11):2699-737. PubMed ID: 22069572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
    Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
    Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotoxins.
    Press OW
    Biotherapy; 1991; 3(1):65-76. PubMed ID: 2009215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacokinetics and hepatotoxic effects of saporin and ricin A-chain immunotoxins on murine liver parenchymal cells.
    Blakey DC; Skilleter DN; Price RJ; Watson GJ; Hart LI; Newell DR; Thorpe PE
    Cancer Res; 1988 Dec; 48(24 Pt 1):7072-8. PubMed ID: 3263899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the embryotoxic effects of saporin, agrostin (type 1 ribosome-inactivating proteins) and ricin (a type 2 ribosome-inactivating protein).
    Chan WY; Ng TB
    Pharmacol Toxicol; 2001 Jun; 88(6):300-3. PubMed ID: 11453369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.
    Polito L; Bortolotti M; Pedrazzi M; Bolognesi A
    Toxins (Basel); 2011 Jun; 3(6):697-720. PubMed ID: 22069735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribosome-inactivating proteins: from toxins to useful proteins.
    Stirpe F
    Toxicon; 2013 Jun; 67():12-6. PubMed ID: 23462379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA; French RR; Amlot P; Gromo G; Modena D; Glennie MJ
    Cancer Res; 1993 Jul; 53(13):3015-21. PubMed ID: 7686448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.